Figures & data
![](/cms/asset/37f90ee6-1b81-4cf3-b944-1ca77f96aa8c/kbie_a_2056813_uf0001_oc.jpg)
Figure 1. Bioinformatics analysis predicts GC-related differentially expressed miRNAs and their potential downstream mRNAs. A: A heat map of differential expression of miRNAs in GC samples based on GC-related miRNA expression dataset GSE93415. B: The intersection of predicted target genes of miR-642b-3p by the TargetScan and miRDB databases and down-regulated genes in GC samples in the GC-related gene expression datasets GSE19826 and GSE79973. C, The expression of CSMD1 in GC samples in the GSE19826 dataset. D: The expression of CSMD1 in GC samples in the GSE79973 dataset.
![Figure 1. Bioinformatics analysis predicts GC-related differentially expressed miRNAs and their potential downstream mRNAs. A: A heat map of differential expression of miRNAs in GC samples based on GC-related miRNA expression dataset GSE93415. B: The intersection of predicted target genes of miR-642b-3p by the TargetScan and miRDB databases and down-regulated genes in GC samples in the GC-related gene expression datasets GSE19826 and GSE79973. C, The expression of CSMD1 in GC samples in the GSE19826 dataset. D: The expression of CSMD1 in GC samples in the GSE79973 dataset.](/cms/asset/426723c8-5c24-4a6a-b455-346e5e2b25a4/kbie_a_2056813_f0001_oc.jpg)
Figure 2. miR-642b-3p is highly expressed in GC tissues and cells. A: miR-642b-3p expression in GC tissues (n = 30) and adjacent normal tissues (n = 30) determined by qRT-PCR; * p < 0.05 versus the adjacent normal tissues; B: miR-642b-3p expression in normal gastric mucosal epithelial cell line GES-1 and GC cell lines SNU-5, AGS, MKN-74, HGC-27 and KATO III determined by qRT-PCR; * p < 0.05 versus the GES-1 cell line, # p < 0.05 versus the SNU-5 cell line. Measurement data were presented as mean ± standard deviation. Data between two groups were performed by independent sample t-test. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. The cell experiment was repeated three times independently.
![Figure 2. miR-642b-3p is highly expressed in GC tissues and cells. A: miR-642b-3p expression in GC tissues (n = 30) and adjacent normal tissues (n = 30) determined by qRT-PCR; * p < 0.05 versus the adjacent normal tissues; B: miR-642b-3p expression in normal gastric mucosal epithelial cell line GES-1 and GC cell lines SNU-5, AGS, MKN-74, HGC-27 and KATO III determined by qRT-PCR; * p < 0.05 versus the GES-1 cell line, # p < 0.05 versus the SNU-5 cell line. Measurement data were presented as mean ± standard deviation. Data between two groups were performed by independent sample t-test. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. The cell experiment was repeated three times independently.](/cms/asset/c85144ab-4cd1-4088-a79f-a3fd7bd0fbb4/kbie_a_2056813_f0002_oc.jpg)
Figure 3. miR-642b-3p down-regulates the expression of CSMD1 and suppresses the EMT of GC cells. A: The predicted binding sites between miR-642b-3p and CSMD1; B: The binding between miR-642b-3p and CSMD1 verified by dual luciferase reporter assay. C: miR-642b-3p and CSMD1 expression in SNU-5 cells transfected with miR-642b-3p mimic or miR-642b-3p inhibitor determined by qRT-PCR; D: Immunofluorescence staining images of N-cadherin protein in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; E: Immunofluorescence staining images of E-cadherin in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; F: Quantitative analysis of the positive rate of N-cadherin and E-cadherin proteins in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; G: α-SMA, FN, N-cadherin and E-cadherin protein expression in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both determined by western blot normalized to GAPDH. * p < 0.05 versus the miR-642b-3p mimic NC group, # p < 0.05 versus the CSMD1 NC group, & p < 0.05 versus the CSMD1 group. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. The cell experiment was repeated three times independently.
![Figure 3. miR-642b-3p down-regulates the expression of CSMD1 and suppresses the EMT of GC cells. A: The predicted binding sites between miR-642b-3p and CSMD1; B: The binding between miR-642b-3p and CSMD1 verified by dual luciferase reporter assay. C: miR-642b-3p and CSMD1 expression in SNU-5 cells transfected with miR-642b-3p mimic or miR-642b-3p inhibitor determined by qRT-PCR; D: Immunofluorescence staining images of N-cadherin protein in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; E: Immunofluorescence staining images of E-cadherin in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; F: Quantitative analysis of the positive rate of N-cadherin and E-cadherin proteins in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; G: α-SMA, FN, N-cadherin and E-cadherin protein expression in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both determined by western blot normalized to GAPDH. * p < 0.05 versus the miR-642b-3p mimic NC group, # p < 0.05 versus the CSMD1 NC group, & p < 0.05 versus the CSMD1 group. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. The cell experiment was repeated three times independently.](/cms/asset/2065bd5a-4dcc-4982-942c-6851ad8c77f2/kbie_a_2056813_f0003_oc.jpg)
Figure 4. miR-642b-3p down-regulates the expression of CSMD1 and impedes the migration and invasion of GC cells. A: Representative images of migration of SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both measured by wound healing assay; B: Quantitative analysis of panel A; C: Representative images of invasion of SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both measured by Transwell assay; D: Quantitative analysis of panel C; E: qRT-PCR detection of relative mRNA expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; F: Protein expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both as determined by western blot normalized to GAPDH. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. * p < 0.05 versus the miR-642b-3p mimic NC group, # p < 0.05 versus the CSMD1 NC group, & p < 0.05 versus the CSMD1 group. The cell experiment was repeated three times independently.
![Figure 4. miR-642b-3p down-regulates the expression of CSMD1 and impedes the migration and invasion of GC cells. A: Representative images of migration of SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both measured by wound healing assay; B: Quantitative analysis of panel A; C: Representative images of invasion of SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both measured by Transwell assay; D: Quantitative analysis of panel C; E: qRT-PCR detection of relative mRNA expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both; F: Protein expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with miR-642b-3p mimic, CSMD1 or both as determined by western blot normalized to GAPDH. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. * p < 0.05 versus the miR-642b-3p mimic NC group, # p < 0.05 versus the CSMD1 NC group, & p < 0.05 versus the CSMD1 group. The cell experiment was repeated three times independently.](/cms/asset/75bac033-5d3b-42a4-9f90-ff4b2ff2c986/kbie_a_2056813_f0004_oc.jpg)
Figure 5. Overexpression of CSMD1 promotes activation of Smad signaling pathway, thus suppressing the EMT, migration and invasion of GC cells. A: qRT-PCR detection of Smad7 and Smad4 mRNA expression in SNU-5 cells treated with CSMD1 or combined with SB431542; B: Representative western blots of Smad7 and Smad4 proteins in SNU-5 cells treated with CSMD1 or combined with SB431542; C: Quantification of Smad7 and Smad4 protein expression in SNU-5 cells treated with CSMD1 or combined with SB431542; In panel A-C, * p < 0.05 versus the CSMD1 group, # p < 0.05 versus the CSMD1 group. D: Immunofluorescence staining images of N-cadherin and E-cadherin proteins in SNU-5 cells treated with CSMD1 or combined with SB431542; E: α-SMA, FN, N-cadherin and E-cadherin protein expression in SNU-5 cells treated with CSMD1 or combined with SB431542 determined by western blot; F: Migration of SNU-5 cells treated with CSMD1 or combined with SB431542 measured by wound healing assay; G: Invasion of SNU-5 cells treated with CSMD1 or combined with SB431542 measured by Transwell assay; H: qRT-PCR detection of relative mRNA expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with CSMD1 or combined with SB431542; I: Protein expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with CSMD1 or combined with SB431542 as determined by western blot. * p < 0.05 versus the CSMD1 NC group. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. The cell experiment was repeated three times independently.
![Figure 5. Overexpression of CSMD1 promotes activation of Smad signaling pathway, thus suppressing the EMT, migration and invasion of GC cells. A: qRT-PCR detection of Smad7 and Smad4 mRNA expression in SNU-5 cells treated with CSMD1 or combined with SB431542; B: Representative western blots of Smad7 and Smad4 proteins in SNU-5 cells treated with CSMD1 or combined with SB431542; C: Quantification of Smad7 and Smad4 protein expression in SNU-5 cells treated with CSMD1 or combined with SB431542; In panel A-C, * p < 0.05 versus the CSMD1 group, # p < 0.05 versus the CSMD1 group. D: Immunofluorescence staining images of N-cadherin and E-cadherin proteins in SNU-5 cells treated with CSMD1 or combined with SB431542; E: α-SMA, FN, N-cadherin and E-cadherin protein expression in SNU-5 cells treated with CSMD1 or combined with SB431542 determined by western blot; F: Migration of SNU-5 cells treated with CSMD1 or combined with SB431542 measured by wound healing assay; G: Invasion of SNU-5 cells treated with CSMD1 or combined with SB431542 measured by Transwell assay; H: qRT-PCR detection of relative mRNA expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with CSMD1 or combined with SB431542; I: Protein expression of metastasis-related genes MMP-2 and MMP-9 in SNU-5 cells treated with CSMD1 or combined with SB431542 as determined by western blot. * p < 0.05 versus the CSMD1 NC group. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. The cell experiment was repeated three times independently.](/cms/asset/e307e5d0-07d5-406c-b90f-853f33362908/kbie_a_2056813_f0005_oc.jpg)
Figure 6. miR-642b-3p downregulates CSMD1 to inactivate the Smad signaling pathway, thereby enhancing the tumor growth of GC cells in nude mice. A: qRT-PCR detection of miR-642b-3p and CSMD1 expression in the tumor tissues of mice treated with miR-642b-3p mimic, CSMD1 or both; B: CSMD1, Smad4 and Smad7 protein expression in the tumor tissues of mice treated with miR-642b-3p mimic, CSMD1 or both; C: Representative photographs of the xenograft tumors in the nude mice treated with miR-642b-3p mimic, CSMD1 or both; D: Quantitative analysis of volume of the xenograft tumor in the nude mice treated with miR-642b-3p mimic, CSMD1 or both; E: Quantitative analysis of weight of the xenograft tumor in the nude mice treated with miR-642b-3p mimic, CSMD1 or both; F: Microvessel density of tumors in nude mice treated with miR-642b-3p mimic, CSMD1 or both as detected by immunohistochemical assay. n = 6. * p < 0.05 versus the miR-642b-3p mimic NC group, # p < 0.05 versus the CSMD1 NC group, & p < 0.05 versus the CSMD1 group. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. Data at various time points were compared by repeated measures ANOVA with Tukey’s post hoc test.
![Figure 6. miR-642b-3p downregulates CSMD1 to inactivate the Smad signaling pathway, thereby enhancing the tumor growth of GC cells in nude mice. A: qRT-PCR detection of miR-642b-3p and CSMD1 expression in the tumor tissues of mice treated with miR-642b-3p mimic, CSMD1 or both; B: CSMD1, Smad4 and Smad7 protein expression in the tumor tissues of mice treated with miR-642b-3p mimic, CSMD1 or both; C: Representative photographs of the xenograft tumors in the nude mice treated with miR-642b-3p mimic, CSMD1 or both; D: Quantitative analysis of volume of the xenograft tumor in the nude mice treated with miR-642b-3p mimic, CSMD1 or both; E: Quantitative analysis of weight of the xenograft tumor in the nude mice treated with miR-642b-3p mimic, CSMD1 or both; F: Microvessel density of tumors in nude mice treated with miR-642b-3p mimic, CSMD1 or both as detected by immunohistochemical assay. n = 6. * p < 0.05 versus the miR-642b-3p mimic NC group, # p < 0.05 versus the CSMD1 NC group, & p < 0.05 versus the CSMD1 group. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA with Tukey’s post hoc test. Data at various time points were compared by repeated measures ANOVA with Tukey’s post hoc test.](/cms/asset/c394f4d9-867a-4d36-9e81-3937c9e3657f/kbie_a_2056813_f0006_oc.jpg)
Supplemental Material
Download Zip (157.1 KB)Data availability statement
The data that supports the findings of this study are available in the manuscript and supplementary materials.